GSK Management

Management Kriterienprüfungen 1/4

GSK's CEO ist Emma Walmsley , ernannt in Apr 2017, hat eine Amtszeit von 7.17 Jahren. Die jährliche Gesamtvergütung beträgt £12.72M , bestehend aus 10.3% Gehalt und 89.7% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.049% der Aktien des Unternehmens, im Wert von £31.87M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 5.5 Jahre bzw. 2.8 Jahre.

Wichtige Informationen

Emma Walmsley

Geschäftsführender

UK£12.7m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	10.3%
Amtszeit als Geschäftsführer	7.2yrs
Eigentum des Geschäftsführers	0.05%
Durchschnittliche Amtszeit des Managements	5.5yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	2.8yrs

Jüngste Management Updates

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For GSK plc's (LON:GSK) CEO For Now

May 02

Recent updates

GSK (LON:GSK) Will Pay A Dividend Of £0.15

May 05

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For GSK plc's (LON:GSK) CEO For Now

May 02

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Emma Walmsley im Vergleich zu den Einnahmen von GSK verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	UK£4b
Dec 31 2023	UK£13m	UK£1m	UK£5b
Sep 30 2023	n/a	n/a	UK£6b
Jun 30 2023	n/a	n/a	UK£5b
Mar 31 2023	n/a	n/a	UK£4b
Dec 31 2022	UK£8m	UK£1m	UK£4b
Sep 30 2022	n/a	n/a	UK£3b
Jun 30 2022	n/a	n/a	UK£4b
Mar 31 2022	n/a	n/a	UK£4b
Dec 31 2021	UK£8m	UK£1m	UK£3b
Sep 30 2021	n/a	n/a	UK£4b
Jun 30 2021	n/a	n/a	UK£4b
Mar 31 2021	n/a	n/a	UK£5b
Dec 31 2020	UK£7m	UK£1m	UK£5b
Sep 30 2020	n/a	n/a	UK£6b
Jun 30 2020	n/a	n/a	UK£7b
Mar 31 2020	n/a	n/a	UK£5b
Dec 31 2019	UK£8m	UK£1m	UK£5b
Sep 30 2019	n/a	n/a	UK£5b
Jun 30 2019	n/a	n/a	UK£4b
Mar 31 2019	n/a	n/a	UK£4b
Dec 31 2018	UK£6m	UK£1m	UK£4b
Sep 30 2018	n/a	n/a	UK£2b
Jun 30 2018	n/a	n/a	UK£2b
Mar 31 2018	n/a	n/a	UK£1b
Dec 31 2017	UK£5m	UK£965k	UK£2b

Vergütung im Vergleich zum Markt: EmmaDie Gesamtvergütung ($USD16.14M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt UK ($USD5.77M).

Entschädigung vs. Einkommen: EmmaDie Bezüge der Mitarbeiter sind im vergangenen Jahr um mehr als 20 % gestiegen.

Geschäftsführer

Emma Walmsley (55 yo)

7.2yrs

Amtszeit

UK£12,718,000

Vergütung

Dame Emma N. Walmsley serves as an Independent Director of Microsoft Corp. since December 4, 2019. She serves as Chief Executive Officer of GlaxoSmithKline Plc since April 1, 2017. Dame Walmsley served as...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Emma Walmsley	CEO & Director	7.2yrs	UK£12.72m	0.049% £ 31.9m
Julie Brown	CFO & Executive Director	1.2yrs	UK£5.14m	0.0024% £ 1.6m
Shobie Ramakrishnan	Chief Digital & Technology Officer	3.4yrs	keine Daten	keine Daten
Tony Wood	Chief Scientific Officer and Head of R&D	1.8yrs	keine Daten	keine Daten
Sarah Elton-Farr	Head of Investor Relations	no data	keine Daten	keine Daten
James Ford	Senior VP & Group General Counsel of Legal & Compliance	5.8yrs	keine Daten	keine Daten
Sally Jackson	Senior Vice President of Global Communications & CEO Office	5.3yrs	keine Daten	keine Daten
David Redfern	President of Corporate Development	no data	keine Daten	keine Daten
Diana Conrad	Chief People Officer	5.2yrs	keine Daten	keine Daten
Philip Thomson	President of Global Affairs	7.2yrs	keine Daten	0.0056% £ 3.7m
Luke Miels	Chief Commercial Officer	6.8yrs	keine Daten	keine Daten
Kevin Sin	Senior VP & Head of Worldwide Business Development for Pharmaceuticals Research Development	6yrs	keine Daten	keine Daten

5.5yrs

Durchschnittliche Betriebszugehörigkeit

55yo

Durchschnittliches Alter

Erfahrenes Management: GSKDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (5.5 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Emma Walmsley	CEO & Director	7.4yrs	UK£12.72m	0.049% £ 31.9m
Julie Brown	CFO & Executive Director	1.1yrs	UK£5.14m	0.0024% £ 1.6m
Jonathan Symonds	Non-Executive Chairman	4.8yrs	UK£765.00k	0.0017% £ 1.1m
Vishal Sikka	Independent Non-Executive Director	1.9yrs	UK£147.00k	0.00026% £ 170.1k
Hal Barron	Non-Executive Director	6.4yrs	UK£356.92k	0.032% £ 20.9m
Harry Dietz	Independent Non-Executive Director	2.4yrs	UK£207.09k	0.00014% £ 91.6k
Anne Beal	Independent Non-Executive Director	3.1yrs	UK£174.93k	0.00015% £ 98.1k
Wendy Mira Becker	Independent Non-Executive Director	less than a year	UK£32.00k	0.000020% £ 13.1k
Charles Bancroft	Senior Independent Non-Executive Director	4.1yrs	UK£323.00k	0.0012% £ 811.4k
Tsun-Huei Lee	Independent Non-Executive Director	less than a year	keine Daten	keine Daten
Elizabeth Anderson	Independent Non-Executive Director	1.8yrs	UK£127.86k	0.000070% £ 45.8k
Jesse Goodman	Independent Non-Executive Director	8.4yrs	UK£173.36k	0.00070% £ 458.0k

2.8yrs

Durchschnittliche Betriebszugehörigkeit

62yo

Durchschnittliches Alter

Erfahrener Vorstand: GSKDie Vorstandsmitglieder gelten nicht als erfahren ( 2.8 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.

GSK Management

Management Kriterienprüfungen 1/4

Wichtige Informationen

Jüngste Management Updates

Gsk plc Announces Board Committee Changes

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For GSK plc's (LON:GSK) CEO For Now

GSK plc, Annual General Meeting, May 08, 2024

GSK plc Appoints Hal Dietz as Member of Nominations & Corporate Governance Committee, Effective 11 March 2024

CEO & Director exercised options and sold UK£2.3m worth of stock

Recent updates

GSK plc Announces That the US Food and Drug Administration (FDA) Has Approved Arexvy

GSK plc (LSE:GSK) acquired Elsie Biotechnologies for $50 million.

GSK plc Announces Positive Results from an Interim Analysis of the DREAMM-8 Phase III Head-To-Head Trial Evaluating Belantamab Mafodotin

GSK plc Provides Litigation Update

An unknown buyer intended to acquire 4.2% stake in Haleon plc (LSE:HLN) from GSK plc (LSE:GSK) for £1.2 billion.

GSK Announces Intention to Sell Approximately 385 Million Shares in Haleon

Gsk plc Announces Board Committee Changes

GSK (LON:GSK) Will Pay A Dividend Of £0.15

First quarter dividend of UK£0.15 announced

GSK plc to Report Q2, 2024 Results on Jul 31, 2024

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For GSK plc's (LON:GSK) CEO For Now

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

GSK plc Announces the US Food and Drug Administration Accepted the Supplemental Biologics License Application for Jemperli

These 4 Measures Indicate That GSK (LON:GSK) Is Using Debt Reasonably Well

GSK plc Announces Positive Results from the Pivotal Eagle-1 Phase III Trial for Gepotidacin

GSK plc Announces US Food and Drug Administration Accepts for Review Biologics License Application for its 5-in-1 Meningococcal ABCWY (MenABCWY) Vaccine Candidate

GSK plc, Annual General Meeting, May 08, 2024

GSK plc Appoints Hal Dietz as Member of Nominations & Corporate Governance Committee, Effective 11 March 2024

GSK plc Announces Positive Headline Results from an Interim Analysis of the Dreamm-8 Phase Iii Head-To-Head Trial Evaluating Blenrep (Belantamab Mafodotin)

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

GSK plc Reaches a Confidential Settlement with Boyd/Steenvoord

CEO & Director exercised options and sold UK£2.3m worth of stock

GSK plc (LSE:GSK) completed the acquisition of Aiolos Bio, Inc. from a group of shareholders.

Upcoming dividend of UK£0.16 per share at 3.5% yield

GSK plc Receives US Food and Drug Administration Fast Track Designation for Bepirovirsen in Chronic Hepatitis B

Center for Drug Evaluation Accepts to Review GSK's Regulatory Application for Shingrix for the Prevention of Shingles in at-Risk Adults Aged 18 and over

GSK's (LON:GSK) Solid Earnings Are Supported By Other Strong Factors

Gsk plc Announces Results from an Interim Analysis of The DREAMM-7 Phase III Head-To-Head Trial

GSK plc to Report Q1, 2024 Results on May 01, 2024

Fourth quarter dividend of UK£0.16 announced

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

GSK plc Provides an Update on Zantac (Ranitidine) Litigation

GSK plc Provides Earnings Guidance for the Year 2024

European Medicines Agency Accepts GSK's Arexvy Filing for Adults 50-59 At Risk

Price target increased by 10% to UK£19.22

We Think GSK (LON:GSK) Can Stay On Top Of Its Debt

GSK plc to Report Q4, 2023 Results on Jan 31, 2024

GSK plc (LSE:GSK) entered into an agreement to acquire Aiolos Bio, Inc. from a group of shareholders for $1.4 billion.

Insufficient Growth At GSK plc (LON:GSK) Hampers Share Price

GSK plc Announces Positive Headline Results from Planned Analysis of Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO Phase III Trial

GSK plc Announces Japan's Ministry of Health, Labour and Welfare Accepts Arexvy Regulatory Application to Prevent RSV Disease in Adults Aged 50-59 At Increased Risk

Japan's Ministry of Health, Labour and Welfare Accepts Arexvy Regulatory Application to Prevent RSV Disease in Adults Aged 50-59 At Increased Risk

Gsk plc Announces It's Jemperli (Dostarlimab) Plus Chemotherapy Approved as the First and Only Frontline Immuno-Oncology Treatment in the European Union for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

GSK plc Announces Positive Results from DREAMM-7 Head-To-Head Phase III Trial for Blenrep in Relapsed/Refractory Multiple Myeloma

GSK plc Announces Positive Results from DREAMM-7 Head-To-Head Phase III Trial for Blenrep in Relapsed/Refractory Multiple Myeloma

GSK Receives Positive CHMP Opinion Recommending Momelotinib for Myelofibrosis Patients with Anaemia

Upcoming dividend of UK£0.14 per share at 4.3% yield

GSK (LON:GSK) Has Announced A Dividend Of £0.14

Gsk plc Revises Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Gsk plc Announces Positive Headline Results from Planned Analysis of Part 1 of the Ruby/Engot-En6/Gog3031/Nsgo Phase Iii Trial

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter